



Innovative Cell and Tissue Technology

Press release
October 6, 2008
Kungsbacka, Sweden

Election committee for Vitrolife AB (publ)

The following people have been appointed as members of Vitrolife's election committee for the Annual General Meeting in 2009:

Henrik Blomquist, representing Skanditek Industriförvaltning
Johan Ståhl, representing Lannebo Fonder
Henrietta Theorell Malmsäter, representing SEB Fonder
Patrik Tigerschiöld, Chairman of the Board

The appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of Vitrolife on May 10, 2005.

The Annual General Meeting of Vitrolife AB (publ) will be held on April 27, 2009 in Gothenburg.

Shareholders who wish to have an item considered at the Annual General Meeting can submit a request to the Board to this effect. Such a request for an item to be considered is to be sent to Vitrolife AB (publ), Att: Chairman of the Board, Box 9080, 400 92 Gothenburg (as from November 1, 2008), and must have been received by the Board no later than seven weeks before the Annual General Meeting, or otherwise in such good time that the matter, where necessary, can be included in the notice to attend the Annual General Meeting.

October 6, 2008
Kungsbacka, Sweden

Vitrolife AB (publ)

Queries should be addressed to:

Patrik Tigerschiöld, Chairman of the Board, phone +46 8 614 00 20.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media) and advanced one-time instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 140 employees and the company's products are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and there are subsidiaries in Sweden, USA, Australia and Italy. The Vitrolife share is listed on the OMX Nordic Exchange Stockholm's Nordic Small Cap list.

Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Homepage: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

The information in this press release is such as that which Vitrolife is required to publish in accordance with the Securities Exchange and Clearing Operations Act. The information was submitted for publication on October 6, 2008 at 4.00 pm.